← Back to patent-cliff list
CAS 2306275-33-0
6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane
Codes：SELP-027
Application context (from source-drug indications)
实体瘤塞普替尼甲状腺髓样癌塞普替尼非小细胞肺癌塞普替尼甲状腺瘤塞普替尼
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 塞普替尼Selpercatinib | Tier C — Watch / trade | 2032 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2,2-dimethyloxirane→4-(6-fluoropyridin-3-yl)-6-(2-hydroxy-2-methylpropoxy)pyrazolo[1,5-a]pyridine-3-carbonitrile→4-(6-fluoropyridin-3-yl)-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile→6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.